Indaptus discontinues Decoy20 enrollment, no active clinical programs; Q2 net loss $1.8M

Indaptus Therapeutics, Inc.

Q2 2026 net loss $1.8M vs $5.2M in Q2 2025; six-month loss $4.3M vs $9.8M; EPS loss $0.02 vs $9.09.
Decoy20 enrollment discontinued; no participants remain in any clinical study; no active clinical development programs.
June 17, 2026 private placement: 20M shares at $0.60/share, $12.0M gross proceeds; cash+investments $11.6M at June 30.
R&D expenses down 83% to $0.4M (Q2) and $0.9M (six months); G&A down 37% to $1.4M (Q2).
Annual meeting elected David Natan, Tim Ruan, Dr. Johnny Fox Arrowsmith as Class II directors; approved 2026 equity plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.